Jonathan Corren, MD / Mario Castro, MD - Beyond Airway Inflammation: Examining the Potential Clinical Utility of Mucus Plugging and Airway Hyperresponsiveness in Severe Asthma to Assess Severity and G

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/VQT865. CME/MOC/AAPA credit will be available until December 18, 2024.Beyond Airway Inflammation: Examining the Potential Clinical Utility of Mucus Plugging and Airway Hyperresponsiveness in Severe Asthma to Assess Severity and Guide Biologic Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJonathan Corren, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Speaker for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi.Co-Chair/PlannerMario Castro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allakos Inc.; Amgen Inc.; Arrowhead Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OM Pharma Ltd.; Pfizer; Pioneering Medicines; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from American Lung Association (ALA); AstraZeneca; Gala Therapeutics, Inc.; Genentech, Inc.; GSK; National Institutes of Health (NIH); Novartis Pharmaceuticals Corporation; Patient-Centered Outcomes Research Institute (PCORI); Pulmatrix, Inc.; Sanofi-Aventis; Shionogi & Co., Ltd; and Theravance Biopharma.Speaker for Amgen Inc.; AstraZeneca; Genentech, Inc.; Regeneron Pharmaceuticals Inc.; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc.Stock Shareholder in Aer Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.